Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer

Conditions

Lung

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous PD-L1 positive NSCLC.

Find out more about who can participate in this trial

Trial with
Yale Cancer Center
Start Date
03/03/2022
End Date
03/01/2023

For more information about this study, contact:

Jennifer Pope

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sarah Goldberg, MD, MPH
Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Research Director, Center for Thoracic Cancers

Sub-Investigators

Last Updated
05/20/2022
Study HIC
#2000030093

Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information